GDC 0853

Drug Profile

GDC 0853

Alternative Names: Bruton’s tyrosine kinase inhibitor - Genentech; GDC-0853; RG 7845; RO 7010939

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Phase I Autoimmune disorders
  • Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Dec 2016 Genentech initiates an extension phase II trial for Rheumatoid arthritis (Adjunctive treatment, Treatment-experienced) in USA (PO, Tablet) (NCT02983227)
  • 11 Nov 2016 Pooled safety and pharmacokinetic results from the phase I trials were presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP - 2016)
  • 14 Sep 2016 Genentech plans a phase II trial for Systemic lupus erythematosus in USA, Argentina, Brazil, Bulgaria, Chile, Colombia, France, South Korea, Mexico, Spain, Thailand and United Kingdom (NCT02908100)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top